科研之友
微信
新浪微博
Facebook
分享链接
摘要
Alzheimer's disease is arguably the largest healthcare issue of our time, with over 45 million people currently diagnosed with dementia worldwide. With the single biggest risk factor being age, this number is only going to increase as our populations' age. Alzheimer's disease pathology is highly complex, but is believed to be principally the result of an inter-play between the toxic proteins beta-amyloid and tau and driven by several genetic and environmental risk factors. Current treatments focus on treating cognitive and behavioral symptoms but have only modest effects and duration of efficacy. To discuss these topics, a 1-day symposium was held in Brussels to look at the progress that the field has made over recent years in attempting to target different aspects and stages of Alzheimer's disease pathology and what lessons have been learned. It also looked at the current biological mechanisms under clinical and preclinical evaluation, together with exploring how new and developing genetic insights into the disease are directing us to novel mechanisms for potential new treatment options and to address the critical question: "Are we making progress towards a disease-modifying treatment for patients?"
- 出版日期2016-7
